Skip to main content

Table 2 Comparison of the in vitro biological potency of the amikacin products studied

From: Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model

Product

Escherichia coli SIG-1

Pseudomonas aeruginosa ATCC 27853

MIC

Min

Max

MBC

Min

Max

MIC

Min

Max

MBC

Min

Max

BMS

1.59

1.00

2.00

1.78

1.00

2.00

4.00

4.00

4.00

10.08

8.00

16.00

Carlon

4.00

4.00

4.00

8.00

8.00

8.00

5.66

4.00

8.00

5.66

4.00

8.00

FormasG

4.00

4.00

4.00

4.00

4.00

4.00

5.66

4.00

8.00

8.00

8.00

8.00

Gencol

2.00

2.00

2.00

2.00

2.00

2.00

4.00

4.00

4.00

8.00

4.00

16.00

Genven

2.00

2.00

2.00

2.00

2.00

2.00

2.83

2.00

4.00

5.66

4.00

8.00

Pisa

2.00

2.00

2.00

2.83

2.00

4.00

4.00

4.00

4.00

11.31

8.00

16.00

Quimicol

2.83

1.00

8.00

4.00

2.00

8.00

3.36

2.00

4.00

6.73

4.00

16.00

Scalpi

2.83

2.00

4.00

2.83

2.00

4.00

4.00

4.00

4.00

4.00

4.00

4.00

Serpharma**

19.03

16.00

32.00

22.63

16.00

32.00

38.05

32.00

64.00

64.00

64.00

64.00

Sigma

1.41

1.00

2.00

2.83

2.00

4.00

4.00

4.00

4.00

8.00

8.00

8.00

Zokumey

2.00

2.00

2.00

4.00

2.00

8.00

4.00

4.00

4.00

11.31

8.00

16.00

  1. Concentrations are expressed as geometric mean and range (Min. and Max) in mg/L
  2. MIC minimal inhibitory concentration, MBC minimal bactericidal concentration
  3. ** p value <0.05 by Dunn’s multiple comparison test